P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB.

Autor:	Nakamura, R., Hendricks, R., Dokhaei, R., Susilo, M., Wilson, D., Trudel, S., Cohen, A., Harrison, S. J., Krishnan, A., Fonseca, R., Adamkewicz, J. I., Li, M., Wong, C., Cooper, J., Sumiyoshi, T.
Zdroj:	HemaSphere; 2022 Supplement 3, Vol. 6, p852-853, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text